BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11:12-7. [PMID: 22251465 DOI: 10.1016/s1499-3872(11)60119-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Li X, Du X, Zhang H, Wu Z, Ren K, Han X. The Interaction Between lncRNA SNHG1 and miR-140 in Regulating Growth and Tumorigenesis via the TLR4/NF-κB Pathway in Cholangiocarcinoma. Oncol Res 2019;27:663-72. [PMID: 30764893 DOI: 10.3727/096504018X15420741307616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Queen T, Adler DG. Stent placement in perihilar cholangiocarcinoma. Clin Liver Dis (Hoboken) 2014;3:74-8. [PMID: 30992890 DOI: 10.1002/cld.323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Ding G, Yang Y, Cao L, Chen W, Wu Z, Jiang G. A modified Jarnagin-Blumgart classification better predicts survival for resectable hilar cholangiocarcinoma. World J Surg Oncol. 2015;13:99. [PMID: 25889726 DOI: 10.1186/s12957-015-0526-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Bencini L, Bernini M, Farsi M. Laparoscopic approach to gastrointestinal malignancies: Toward the future with caution. World J Gastroenterol 2014; 20(7): 1777-1789 [PMID: 24587655 DOI: 10.3748/wjg.v20.i7.1777] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Jiang P, Mu PY, Zhou NX, Bai YY. Clinical effects of laparoscopic ultrasound imaging in robot-assisted abdominal surgery. Shijie Huaren Xiaohua Zazhi 2013; 21(11): 1046-1049 [DOI: 10.11569/wcjd.v21.i11.1046] [Reference Citation Analysis]
6 Paik WH, Loganathan N, Hwang JH. Preoperative biliary drainage in hilar cholangiocarcinoma: When and how? World J Gastrointest Endosc 2014; 6(3): 68-73 [PMID: 24634710 DOI: 10.4253/wjge.v6.i3.68] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
7 Kim BH, Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW. Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. Am J Clin Oncol 2017;40:158-62. [PMID: 25171299 DOI: 10.1097/COC.0000000000000121] [Reference Citation Analysis]
8 Sun Q, Li F, Yu S, Zhang X, Shi F, She J. Pontin Acts as a Potential Biomarker for Poor Clinical Outcome and Promotes Tumor Invasion in Hilar Cholangiocarcinoma. Biomed Res Int 2018;2018:6135016. [PMID: 29862278 DOI: 10.1155/2018/6135016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhou QX, Jiang XM, Wang ZD, Li CL, Cui YF. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis. Med Oncol 2015;32:105. [PMID: 25744243 DOI: 10.1007/s12032-015-0553-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
10 Qin X, Lu M, Zhou Y, Li G, Liu Z. LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells. Cell Cycle 2019;18:889-97. [PMID: 30983519 DOI: 10.1080/15384101.2019.1598726] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
11 Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, Cui J, Zheng P, Lai J, Zhang Y, Bai J, Jiang P, Zhu J, He Y, Wang J. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF‑κB pathway activation. Int J Oncol 2020;56:101-12. [PMID: 31746424 DOI: 10.3892/ijo.2019.4907] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Goral V. Cholangiocarcinoma: New Insights. Asian Pac J Cancer Prev 2017;18:1469-73. [PMID: 28669153 DOI: 10.22034/APJCP.2017.18.6.1469] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015;30:159-171. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
14 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
15 Xu Y, Leng K, Li Z, Zhang F, Zhong X, Kang P, Jiang X, Cui Y. The prognostic potential and carcinogenesis of long non-coding RNA TUG1 in human cholangiocarcinoma. Oncotarget 2017;8:65823-35. [PMID: 29029475 DOI: 10.18632/oncotarget.19502] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
16 Pan H, Liang Z, Yin TS, Xie Y, Li DW. Hepato-biliary-enteric stent drainage as palliative treatment for proximal malignant obstructive jaundice. Med Oncol 2014;31:853. [PMID: 24464214 DOI: 10.1007/s12032-014-0853-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS, Chung JB, Kim KS. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012;16:1672-9. [PMID: 22798185 DOI: 10.1007/s11605-012-1960-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
18 Czhao AV, Shevchenko TV, Zharikov YO. [View on the problem of Klatskin tumor]. Khirurgiia (Mosk) 2015;:62-7. [PMID: 26103646 DOI: 10.17116/hirurgia2015462-67] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H, Sun B, Yin D, Sun J, Song R. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 2015;6:17206-17220. [PMID: 26015398 DOI: 10.18632/oncotarget.4043] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 13.2] [Reference Citation Analysis]
20 Yin DL, Liang YJ, Zheng TS, Song RP, Wang JB, Sun BS, Pan SH, Qu LD, Liu JR, Jiang HC, Liu LX. EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma. Sci Rep 2016;6:32167. [PMID: 27571770 DOI: 10.1038/srep32167] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]